Drilldown: Medicines
Medicines > classes 
:
Dissociative or
Neuroleptic or
[[:Category:Bowel_preparation_agents|Bowel preparation agent]]
:
Dissociative or
Neuroleptic or
[[:Category:Bowel_preparation_agents|Bowel preparation agent]] Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Asenapine (1) ·
Chlorpromazine (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Droperidol (1) ·
Ephenidine (1) ·
Eticyclidine (1) ·
Fluphenazine (1) ·
Ibogaine (1) ·
Iloperidone (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Methoxetamine (1) ·
Molindone (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Pimozide (1) ·
Polyethylene glycol 3350 (PEG 3350) (1) ·
Polyethylene glycol 3350 with electrolytes (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Trifluoperazine (1) ·
Xenon (1) ·
Ziprasidone (1)
brand:
None (17) ·
DXM (1) ·
DXO (1) ·
Fanapt (1) ·
Geodon (1) ·
GoLYTELY, NuLYTELY, TriLyte, MoviPrep, Plenvu, Gavilyte (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) ·
Moban (1) ·
Navane (1) ·
Orap (1) ·
Prolixin (1) ·
Saphris (1) ·
Spravato (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Butyrophenone D2 antagonist (1) ·
Contains salvinorin A (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Phenothiazine D2 antagonist (4) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-00000054-QINU`"' The clinical efficacy endpoint is adequate visualization at colonoscopy, scored by the Boston Bowel Preparation Scale'"`UNIQ--ref-00000055-QINU`"'. (1) ·
'"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)
uses:
None (34) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"' (1) ·
'"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1)
starting dose:
None (34) ·
4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake (1) ·
Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (34) ·
Avoid; may cause fetal harm (1) ·
Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not absorbed; generally considered acceptable when bowel prep is required<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 37 results in range #1 to #37.